The risk factors and prevention of stroke in atrial fibrillation
https://doi.org/10.14412/2074-2711-2014-3-55-60
Abstract
Stroke is one of the top three causes of death in the population and a leading cause of disability in the elderly; ischemic stroke (IS) constitutes a major portion (70–85%) of all strokes so its prevention s a relevant problem of modern medicine. Among the risk factors RFs) of stroke, nonvalvular atrial fibrillation (AF) is of great ignificance, which occurs in persons over 70 years of age in pproximately 5–10% of cases and increases the risk of IS 3–4-fold.
The review analyzes RFs for stroke in AF. The CHA2DS2-VASc scale encompassing several RFs is noted to be informative and easy-to-use. There are data of large-scale randomized trials that show that novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) are as good as warfarin or offer an advantage over the latter, by more substantially decreasing the risk of stroke and reducing the likelihood of profuse bleeding, intracranial hemorrhage in particular. There is evidence for the efficacy of rivaroxaban in the secondary prevention of stroke. The authors provide their experience with patient management to prevent recurrent cardioembolic stroke.
In our country, most patients who have sustained IS or transient ischemic attack in the presence of AF do not take warfarin due to the fact that it is difficult to regularly monitor the international normalized ratio (INR). It is noted that the administration of the novel anticoagulants, which differs from that of warfarin, does not require INR monitoring and can increase the number of patients on anticoagulant therapy and therefore reduce the incidence of stroke in the presence of AF.
About the Authors
V. A. Parfenov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991
S. V. Verbitskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991
Russian Federation
Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991
References
1. Суслина ЗА, Фонякин АВ, Гераскина ЛА и др. Практическая кардионеврология. Москва: ИМА-ПРЕСС; 2010. 304 с. [Suslina ZA, Fonyakin AV, Geraskina LA, et al. Prakticheskaya kardionevrologiya [Practical cardioneurology]. Moscow: IMA-PRESS; 2010. 304 p.]
2. Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]
3. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25(5):457–507. DOI: 10.1159/000131083. Epub 2008 May 6.
4. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227–76. DOI: 10.1161/STR.0b013e3181f7d043. Epub 2010 Oct 21.
5. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236. DOI: 10.1161/STR.0000000000000024. Epub 2014 May 1.
6. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–54.
7. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429. DOI: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29.
8. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. DOI: 10.1136/bmj.d124.
9. Hart RG, Pearce LA, Aguilar M. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
12. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.
13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
14. Camm AJ, Lip GY, de Caterina R, et al. 2012 focused up date of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.
15. Вербицкая СВ, Парфенов ВА. Вторичная профилактика инсульта в амбулаторных условиях. Неврологический журнал. 2011;16(1):42–6. [Verbitskaya SV, Parfenov VA. The secondary prevention of stroke in outpatient conditions. Nevrologicheskii zhurnal. 2011;16(1):42–6. (In Russ.)]
16. Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther. 2014:8:789–98. DOI: 10.2147/DDDT.S45644.
17. Harris K, Mant J. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. Int J Clin Pract. 2013;67:647–55.
18. Шандалин ВА, Фонякин АВ, Гераскина ЛА. Вторичная профилактика ишемического инсульта: от рекомендаций – к реальной клинической практике. Неврология, нейропсихиатрия, психосоматика. 2012;(2):35–41. [Shandalin VA, Fonyakin AV, Geraskina LA. Secondary prevention of ischemic stroke: from recommendations to real clinical practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;(2):35–41. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2012-379.
19. Beyer-Westendorf J. Updated results of the prospective NOAC registry. Available from: https://ash.confex.com/ash/2012/webprogram/Paper49970.html
20. Camm AJ, Amarenco P, Haas S, et al. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag. 2014 Jul 17;10:425–34. DOI: 10.2147/VHRM.S63298.
Review
For citations:
Parfenov V.A., Verbitskaya S.V. The risk factors and prevention of stroke in atrial fibrillation. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(3):55-60. (In Russ.) https://doi.org/10.14412/2074-2711-2014-3-55-60
Views: 940
Email this article 